Julia S. Kim, Esq.
Julia Kim joined Pergament & Cepeda in September 2021, with over fifteen years of experience litigating Hatch-Waxman actions, including as a partner at a big law firm and a partner at a patent firm in New York City. She has litigated Hatch-Waxman actions involving aripiprazole, plerixafor, fexofenadine, pantoprazole, bupropion HCl, omeprazole, among others. She has drafted briefs and accompanying submissions to oppose motions for temporary and permanent injunctive relief in connection with launches of generic products for aripiprazole, fexofenadine, pantoprazole, buprophion HCl, zoledronic acid, metaxalone, and oxandralone. She has represented generic pharmaceutical companies as a sole defendant in a process patent action and in Hatch-Waxman actions, and also as a member of joint defendant groups in consolidated Hatch-Waxman actions. Her involvement in a Hatch-Waxman action typically starts with the pleading stage and proceeds through to a final court decision on the merits and appeal.
Ms. Kim has also opposed applications seeking discovery for use in foreign or international intellectual property proceedings under 28 U.S.C. § 1782.
Admissions: New York (1992); New Jersey (2018); USPTO (1993).
Education: Lehigh University (B.S.I.E.); Fordham Law.
Practice Areas: Pharmaceutical patent litigation; patent litigation; litigation under 28 U.S.C. § 1782.